期刊
JOURNAL OF KOREAN MEDICAL SCIENCE
卷 24, 期 1, 页码 46-51出版社
KOREAN ACAD MEDICAL SCIENCES
DOI: 10.3346/jkms.2009.24.1.46
关键词
Pituitary ACTH Hypersecretion; Pituitary Adenoma; Outcome Assessment (Health Care)
It has been suggested that the patients with Cushing's disease secondary to pituitary macroadenomas (>10 mm) have higher basal adrenocorticotropic hormone (ACTH) levels, which are less suppressible on high-dose dexamethasone suppression tests (HDDST). We compared the clinical and biochemical characteristics of patients with macroadenomas (N=7) and microadenomas (N=23) who were diagnosed at Samsung Medical Center in Korea between 1996 and 2006. Basal moming plasma ACTH levels were 101.5 +/- 23.2 pg/mL for macroadenoma patients and 83.6 +/- 11.1 pg/mL for microadenoma patients (mean +/- SEMs) (P=0.44). Morning serum cortisol levels were 26.8 +/- 3.2 mu g/dL for macroadenoma patients and 29.5 +/- 2.9 mu g/dL for microadenoma patients (p=0.77). The proportion of patients who showed suppressibility on HDDST was almost identical in the two groups (71.4% [5/7] for macroadenoma patients vs. 72.7% [16/22] for microadenoma patients, p=1.00). Furthermore, the remission rate with trans-sphenoidal surgery was similar between the two groups (100% [5/5] for macroadenoma patients vs. 73.3% [11/15] for microadenoma patients, p=0.53). Thus, tumor size is not a major determinant of hormone secretion or clinical outcomes in patients with Cushing's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据